CO2023016712A2 - Conjugados de neodegradador-anticuerpo anti-cd33 - Google Patents
Conjugados de neodegradador-anticuerpo anti-cd33Info
- Publication number
- CO2023016712A2 CO2023016712A2 CONC2023/0016712A CO2023016712A CO2023016712A2 CO 2023016712 A2 CO2023016712 A2 CO 2023016712A2 CO 2023016712 A CO2023016712 A CO 2023016712A CO 2023016712 A2 CO2023016712 A2 CO 2023016712A2
- Authority
- CO
- Colombia
- Prior art keywords
- neodegrader
- antibody conjugates
- compositions
- conjugates
- neodegraders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163202272P | 2021-06-03 | 2021-06-03 | |
| US202163282588P | 2021-11-23 | 2021-11-23 | |
| PCT/IB2022/055168 WO2022254377A1 (en) | 2021-06-03 | 2022-06-02 | Neodegrader-anti-cd33 antibody conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023016712A2 true CO2023016712A2 (es) | 2024-02-26 |
Family
ID=84323935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0016712A CO2023016712A2 (es) | 2021-06-03 | 2023-12-01 | Conjugados de neodegradador-anticuerpo anti-cd33 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240252671A1 (enExample) |
| EP (1) | EP4346910A4 (enExample) |
| JP (1) | JP2024521919A (enExample) |
| KR (1) | KR20240042598A (enExample) |
| AU (1) | AU2022284372A1 (enExample) |
| CA (1) | CA3222185A1 (enExample) |
| CL (2) | CL2023003605A1 (enExample) |
| CO (1) | CO2023016712A2 (enExample) |
| IL (1) | IL308812A (enExample) |
| MX (1) | MX2023014282A (enExample) |
| PE (1) | PE20250159A1 (enExample) |
| WO (1) | WO2022254377A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250090681A1 (en) * | 2021-06-03 | 2025-03-20 | Orum Therapeutics, Inc. | Neodegrader conjugates |
| EP4527415A1 (en) * | 2022-05-18 | 2025-03-26 | Medilink Therapeutics (Suzhou) Co., Ltd. | Antibody-drug conjugate containing protein degradation agent bioactive compound, method for preparing same, and use thereof |
| KR20250133786A (ko) * | 2023-02-15 | 2025-09-08 | 씨에스피씨 메가리스 바이오파마슈티칼 씨오., 엘티디. | 도마이드계 분자 접착제 유도체 및 이의 용도 |
| WO2024222841A1 (zh) * | 2023-04-27 | 2024-10-31 | 石药集团巨石生物制药有限公司 | 一种抗体药物偶联物 |
| WO2024249235A1 (en) * | 2023-06-01 | 2024-12-05 | Abbvie Inc. | Anti-human cd33 bet degrader antibody-drug conjugates |
| CN122422333A (zh) * | 2023-10-17 | 2026-07-17 | 百时美施贵宝公司 | Gspt1降解化合物、抗cd33抗体和抗体-药物缀合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5238936B2 (ja) * | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| CA2957226C (en) * | 2008-10-29 | 2018-08-14 | Celgene Corporation | Isoindoline compounds for use in the treatment of cancer |
| KR101870555B1 (ko) * | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| PL2822575T3 (pl) * | 2012-03-03 | 2020-08-10 | Immungene, Inc. | Zmodyfikowane sposobami inżynierii cząsteczki fuzyjne przeciwciało-mutant interferonu |
| US20180312561A1 (en) * | 2015-06-12 | 2018-11-01 | Immungene, Inc. | Focused interferon immunotherapy for treatment of cancer |
| CN104994263B (zh) * | 2015-06-30 | 2016-12-28 | 广东欧珀移动通信有限公司 | 一种摄像装置及具有该摄像装置的终端 |
| CN109152843A (zh) * | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| US20230338564A1 (en) * | 2020-03-31 | 2023-10-26 | Orum Therapeutics, Inc. | Neodegrader conjugates |
-
2022
- 2022-06-02 AU AU2022284372A patent/AU2022284372A1/en active Pending
- 2022-06-02 CA CA3222185A patent/CA3222185A1/en active Pending
- 2022-06-02 IL IL308812A patent/IL308812A/en unknown
- 2022-06-02 MX MX2023014282A patent/MX2023014282A/es unknown
- 2022-06-02 WO PCT/IB2022/055168 patent/WO2022254377A1/en not_active Ceased
- 2022-06-02 US US18/566,805 patent/US20240252671A1/en active Pending
- 2022-06-02 JP JP2023574587A patent/JP2024521919A/ja active Pending
- 2022-06-02 EP EP22815474.6A patent/EP4346910A4/en active Pending
- 2022-06-02 PE PE2023003198A patent/PE20250159A1/es unknown
- 2022-06-02 KR KR1020247000100A patent/KR20240042598A/ko active Pending
-
2023
- 2023-12-01 CO CONC2023/0016712A patent/CO2023016712A2/es unknown
- 2023-12-01 CL CL2023003605A patent/CL2023003605A1/es unknown
-
2026
- 2026-02-10 CL CL2026000399A patent/CL2026000399A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2023003605A1 (es) | 2024-05-03 |
| PE20250159A1 (es) | 2025-01-22 |
| US20240252671A1 (en) | 2024-08-01 |
| JP2024521919A (ja) | 2024-06-04 |
| CA3222185A1 (en) | 2022-12-08 |
| AU2022284372A9 (en) | 2024-01-11 |
| CL2026000399A1 (es) | 2026-03-20 |
| TW202313022A (zh) | 2023-04-01 |
| WO2022254377A1 (en) | 2022-12-08 |
| EP4346910A1 (en) | 2024-04-10 |
| KR20240042598A (ko) | 2024-04-02 |
| MX2023014282A (es) | 2024-02-27 |
| IL308812A (en) | 2024-01-01 |
| EP4346910A4 (en) | 2026-05-06 |
| AU2022284372A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003605A1 (es) | Conjugados de neodegradador-anticuerpo anti-cd33 | |
| MX2023014284A (es) | Conjugados de neodegradadores. | |
| CL2023001800A1 (es) | Conjugados anticuerpo-fármaco específicos para tumores con claudina 18.2 | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
| MX2021007620A (es) | Inmunoconjugados de anticuerpos receptor huerfano similar al receptor tirosina cinasa 1 (ror1). | |
| CL2022001030A1 (es) | Compuestos moduladores de glp-1r | |
| AR113224A1 (es) | Conjugados de anticuerpo que comprenden un agonista de sting | |
| MX2023013995A (es) | Conjugados de anticuerpo y antraciclina. | |
| CL2024002658A1 (es) | Moléculas de unión contra fralfa | |
| ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
| CY1116913T1 (el) | Τροποποιημενα κλασματα fab αντισωματων | |
| CL2023000741A1 (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos. | |
| CY1125181T1 (el) | Ανοσοσυζευγματα που στοχευουν adam9 και μεθοδοι χρησης αυτων | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| CY1118763T1 (el) | Αντισωμα αντι-ερηα2 | |
| CL2025000403A1 (es) | Anticuerpo anti-lilrb1 y usos del mismo | |
| MX2023011121A (es) | Anticuerpos anti antigeno leucocito 37 (cd37) biespecificos, anticuerpos anti antigeno leucocito 37 (cd37) monoclonales y metodos de uso de los mismos. | |
| MX2025000550A (es) | Conjugados anticuerpo-fármaco que se unen a la proteína 1 que contiene el dominio cub (cdcp1) y usos de los mismos | |
| EP4294441A4 (en) | ANTI-CLDN18.2 ANTIBODY CONJUGATES | |
| MX2020010110A (es) | Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos. | |
| CO2025008154A2 (es) | Conjugados anticuerpo–fármaco anti–cea y métodos de uso | |
| CO2023017609A2 (es) | Anticuerpos multiespecíficos anti-cea y anti-cd137 y métodos de uso | |
| MX2025003990A (es) | Conjugados neodegradadores | |
| CO2026002111A2 (es) | Anticuerpos gucy2c y usos de estos |